<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark A Peppercorn, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sunanda V Kane, MD, MSPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jana Al Hashash, MD, MSc, FACG, AGAF</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H12689022"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Inflammatory bowel disease (IBD) is comprised of two major disorders: ulcerative colitis (UC) and Crohn disease (CD). UC affects the colon and is characterized by inflammation of the mucosal layer. CD is characterized by transmural inflammation and may involve any portion of luminal gastrointestinal tract, from the oral cavity to the perianal area. Patterns of CD distribution include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Approximately 80 percent of patients have small bowel involvement, usually in the distal ileum, with one-third of patients having ileitis exclusively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Approximately 50 percent of patients have ileocolitis, which refers to involvement of both the ileum and colon.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Approximately 20 percent have disease limited to the colon. In contrast to rectal involvement in patients with UC, one-half of CD patients with colitis have sparing of the rectum.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Approximately one-third of patients have perianal disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Approximately 5 to 15 percent have involvement of the mouth or gastroduodenal area, while fewer patients have involvement of the esophagus and proximal small bowel. </p><p></p><p>CD can be classified based on age of onset, disease location, and disease behavior (eg, stricturing), and the Montreal classification is commonly used for epidemiologic and population-based studies  (<a class="graphic graphic_table graphicRef86283" href="/z/d/graphic/86283.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/4066.html" rel="external">"Definitions, epidemiology, and risk factors for inflammatory bowel disease"</a>.)</p><p>This topic will review the clinical manifestations, diagnosis, and prognosis of CD in adults. The pathogenesis of IBD is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4077.html" rel="external">"Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease"</a>.)</p><p>Management of patients with CD including assessment of disease activity, severity and risk, is discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4069.html" rel="external">"Overview of the medical management of mild (low risk) Crohn disease in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4084.html" rel="external">"Management of Crohn disease after surgical resection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4082.html" rel="external">"Perianal Crohn disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4079.html" rel="external">"Surveillance and management of dysplasia in patients with inflammatory bowel disease"</a>.)</p><p></p><p class="headingAnchor" id="H12689029"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H1253319772"><span class="h2">Patient presentation</span><span class="headingEndMark"> — </span>Patients with CD can have symptoms for many years prior to diagnosis or they may present acutely [<a href="#rid2">2,3</a>]. </p><p class="headingAnchor" id="H2536922438"><span class="h3">Cardinal symptoms</span><span class="headingEndMark"> — </span>The cardinal symptoms of CD include abdominal pain, diarrhea (with or without gross bleeding), fatigue, and weight loss [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abdominal pain</strong> – Crampy abdominal pain is a common manifestation of CD, regardless of disease distribution:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A patient with disease limited to the distal ileum frequently presents with right lower quadrant abdominal pain. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The transmural nature of the inflammatory process results in fibrotic strictures. These strictures often lead to repeated episodes of abdominal pain and small bowel obstruction, or less commonly colonic obstruction. If the inflammation is aggressive, the transmural nature results in a fistula with abscess formation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Some patients have no symptoms of CD until luminal narrowing causes abdominal pain and early signs of obstruction (fewer bowel movements).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diarrhea</strong> – Diarrhea is a common presentation, but bowel symptoms often fluctuate over a long period of time [<a href="#rid5">5</a>]. A history of persistent but intermittent diarrhea without gross blood and with other features of IBD (eg, skin, eye, or joint problems) suggests the diagnosis of CD. Diarrhea associated with CD may have multiple causes including:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Excessive fluid secretion and impaired fluid absorption by inflamed small or large bowel</p><p class="bulletIndent2"><span class="glyph">•</span>Bile salt malabsorption due to an inflamed terminal ileum</p><p class="bulletIndent2"><span class="glyph">•</span>Steatorrhea related to loss of bile salts</p><p class="bulletIndent2"><span class="glyph">•</span>Enteroenteric fistulas causing bypass of portions of absorptive surface area</p><p></p><p class="bulletIndent1">Stools frequently contain microscopic blood (eg, positive guaiac or immunochemical test); however, some patients with CD with predominantly colonic involvement may have grossly bloody stools.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic symptoms</strong> – Fatigue is a common feature of CD. Weight loss is often related to decreased oral intake because patients with obstructing segments of bowel feel better when they do not eat. Weight loss may also be related to malabsorption.</p><p></p><p class="bulletIndent1">Fever occurs less frequently and may be due to the inflammatory process itself or may be the result of intestinal perforation complicated by an intra-abdominal abscess. (See <a class="local">'Features of transmural inflammation'</a> below.)</p><p></p><p class="headingAnchor" id="H3997588047"><span class="h3">Features of transmural inflammation</span><span class="headingEndMark"> — </span>Transmural bowel inflammation of CD is associated with sinus tracts that may lead to fistulas and phlegmon formation: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fistulas</strong> – Transmural inflammation is associated with sinus tracts that may penetrate the serosa and give rise to fistulas. Penetration of the bowel wall most often presents as an indolent process and not as the acute onset of severe abdominal pain. (See  <a class="medical medical_review" href="/z/d/html/15075.html" rel="external">"Overview of gastrointestinal tract perforation", section on 'Clinical features'</a>.) </p><p></p><p class="bulletIndent1">Fistulas are tracts or communications that connect two epithelial-lined organs. For example, fistulas may connect the intestine to bladder (enterovesical), to skin (enterocutaneous), to bowel (enteroenteric), or to the vagina (enterovaginal).</p><p></p><p class="bulletIndent1">The clinical manifestation of the fistula depends upon the area of involvement adjacent to the diseased bowel segment:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Enteroenteric fistulas may be asymptomatic or present as a palpable mass</p><p class="bulletIndent2"><span class="glyph">•</span>Enterovesical fistulas lead to recurrent urinary tract infections, often with multiple organisms, and to pneumaturia</p><p class="bulletIndent2"><span class="glyph">•</span>Fistulas to the retroperitoneum may lead to psoas abscesses or ureteral obstruction with hydronephrosis</p><p class="bulletIndent2"><span class="glyph">•</span>Enterovaginal fistulas may present with passage of gas or feces through the vagina</p><p class="bulletIndent2"><span class="glyph">•</span>Enterocutaneous fistulas can cause bowel contents to drain to the surface of the skin</p><p></p><p class="bulletIndent1">In a population-based study of 169 patients with CD, 12 patients (7 percent) had evidence of a fistula of any type at least 30 days prior to the diagnosis of CD [<a href="#rid6">6</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Phlegmon/abscess –</strong> All sinus tracts do not lead to fistulas, but may present as a phlegmon, (ie, a walled-off inflammatory mass without bacterial infection) that may be palpated on physical examination of the abdomen. Ileal involvement is suggested by a mass in the right lower quadrant.</p><p></p><p class="bulletIndent1">Some sinus tracts lead to abscess formation and an acute presentation of localized peritonitis with fever, abdominal pain, and tenderness. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Perianal disease</strong> – Symptoms and signs related to perianal disease may occur in approximately one-third of patients during the course of CD. For example, patients with perianal fistula may present with perianal pain and drainage, while patients with perianal abscess present with perianal pain, fever, and purulent discharge. The evaluation and management of perianal CD is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4082.html" rel="external">"Perianal Crohn disease"</a>.)</p><p></p><p class="headingAnchor" id="H12689085"><span class="h3">Other gastrointestinal features</span><span class="headingEndMark"> — </span>The clinical manifestations of other sites of gastrointestinal involvement in CD are variable and occur less frequently than ileocolonic involvement. Examples include:</p><p class="bulletIndent1"><span class="glyph">●</span>Oral involvement may present with aphthous ulcers or pain in the mouth and gums.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Esophageal involvement may present with odynophagia or dysphagia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gastroduodenal involvement is seen in up to 15 percent of patients and may present with upper abdominal pain, nausea, and/or postprandial vomiting [<a href="#rid7">7</a>]. The clinical features of gastroduodenal CD may be similar to those of peptic ulcer disease or gastric outlet obstruction. </p><p></p><p class="bulletIndent1">The distal antrum of the stomach and duodenum are the most commonly affected upper gastrointestinal (GI) sites in patients with CD. Some patients have limited upper GI involvement and may be asymptomatic, while other patients with persistent symptoms have deep ulcerations and longer segments of intestinal involvement. (See  <a class="medical medical_review" href="/z/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults", section on 'Gastroduodenal disease'</a>.)</p><p></p><p class="headingAnchor" id="H2641214413"><span class="h3">Malabsorption</span><span class="headingEndMark"> — </span>Patients with small bowel CD and bile salt malabsorption may present with watery diarrhea and steatorrhea that can lead to protein calorie malnutrition, hypocalcemia, vitamin deficiency (eg, vitamin B12), and metabolic bone disease. (See  <a class="medical medical_review" href="/z/d/html/4780.html" rel="external">"Approach to the adult patient with suspected malabsorption"</a> and <a class="local">'Extraintestinal manifestations'</a> below.) </p><p>Small bowel disease involving greater than 100 cm of terminal ileum usually results in severe impairment of the enterohepatic circulation of bile salts such that the liver's ability to upregulate de novo bile acid synthesis is inadequate to meet normal physiologic needs for bile production, resulting in fat malabsorption. (See  <a class="medical medical_review" href="/z/d/html/4781.html" rel="external">"Overview of nutrient absorption and etiopathogenesis of malabsorption", section on 'Etiopathogenesis of malabsorption'</a>.)</p><p>Shorter segments of terminal ileal disease (ie, &lt;100 cm) may result in chronic diarrhea, even though it may not result in fat malabsorption, since the bile acids that are not absorbed in the small intestine may stimulate water and electrolyte secretion in the colon (which is called "cholerrheic diarrhea").</p><p class="headingAnchor" id="H12689099"><span class="h3">Extraintestinal manifestations</span><span class="headingEndMark"> — </span>Extraintestinal manifestations of CD are generally related to inflammatory disease activity and include  (<a class="graphic graphic_table graphicRef81867" data-inline-graphics="81867" href="/z/d/graphic/81867.html" rel="external">table 2</a>) [<a href="#rid8">8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Arthritis or arthropathy</strong> – Primarily involving large joints in approximately 20 percent of patients without synovial destruction, arthritis is the most common extraintestinal manifestation. Central or axial arthritis, such as sacroiliitis, or ankylosing spondylitis, may also occur. An undifferentiated spondyloarthropathy or ankylosing spondylitis may be the presenting manifestation of CD. (See  <a class="medical medical_review" href="/z/d/html/7787.html" rel="external">"Clinical manifestations and diagnosis of arthritis associated with inflammatory bowel disease and other gastrointestinal diseases"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eye involvement</strong> – Eye manifestations occur in approximately 5 percent of patients and include uveitis, iritis, and episcleritis [<a href="#rid9">9</a>]  (<a class="graphic graphic_picture graphicRef75384 graphicRef70384" href="/z/d/graphic/75384.html" rel="external">picture 1A-B</a>). (See  <a class="medical medical_review" href="/z/d/html/4064.html" rel="external">"Dermatologic and ocular manifestations of inflammatory bowel disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin disorders</strong> – Dermatologic manifestations occur in approximately 10 percent of patients and include erythema nodosum and pyoderma gangrenosum  (<a class="graphic graphic_picture graphicRef71344 graphicRef53733 graphicRef52528" href="/z/d/graphic/71344.html" rel="external">picture 2A-C</a>). Rarely, vulvar involvement of CD may manifest as pain, edema, erythema, and ulceration [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/128406.html" rel="external">"Vulvar lesions: Differential diagnosis of red lesions", section on 'Crohn disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary sclerosing cholangitis</strong> – Primary sclerosing cholangitis typically occurs in approximately 5 percent of patients with CD, who are often asymptomatic but have an elevated serum alkaline phosphatase concentration. (See  <a class="medical medical_review" href="/z/d/html/660.html" rel="external">"Primary sclerosing cholangitis in adults: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other hepatobiliary involvement –</strong> Hepatobiliary disorders in patients with CD are often related to IBD medications rather than the disease itself. However, conditions such as pyogenic liver abscess are rarely seen in association with CD. (See  <a class="medical medical_review" href="/z/d/html/4074.html" rel="external">"Overview of hepatobiliary disorders in patients with inflammatory bowel disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary amyloidosis – </strong>Secondary amyloidosis is very rare but may lead to renal failure and other organ system involvement [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/z/d/html/5602.html" rel="external">"Causes and diagnosis of AA amyloidosis and relation to rheumatic diseases"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Renal stones</strong> – Calcium oxalate and uric acid kidney stones can result from steatorrhea and diarrhea [<a href="#rid12">12</a>]. Uric acid stones can result from dehydration and metabolic acidosis. (See  <a class="medical medical_review" href="/z/d/html/7375.html" rel="external">"Kidney stones in adults: Epidemiology and risk factors"</a> and  <a class="medical medical_review" href="/z/d/html/7378.html" rel="external">"Kidney stones in adults: Uric acid nephrolithiasis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone loss - </strong>Metabolic bone disease may occur as a result of glucocorticoid use and impaired vitamin D and calcium absorption [<a href="#rid13">13,14</a>]. (See  <a class="medical medical_review" href="/z/d/html/2028.html" rel="external">"Metabolic bone disease in inflammatory bowel disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary involvement</strong> – Pulmonary manifestations of IBD include bronchiectasis, chronic bronchitis, interstitial lung disease, bronchiolitis obliterans with organizing pneumonia, sarcoidosis, necrobiotic lung nodules, and pulmonary infiltrates with eosinophilia syndrome. (See  <a class="medical medical_review" href="/z/d/html/4344.html" rel="external">"Pulmonary complications of inflammatory bowel disease", section on 'Primary respiratory involvement'</a>.)</p><p></p><p class="headingAnchor" id="H154188516"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>Physical examination may be normal or show nonspecific signs (eg, weight loss) suggestive of CD. More specific findings include perianal skin tags, sinus tracts, and abdominal tenderness or palpable abdominal mass (typically in the right lower quadrant). </p><p class="headingAnchor" id="H2403860106"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>Routine laboratory tests may be normal or they may reveal anemia, an elevated white blood cell count, an elevated C-reactive protein, electrolyte abnormalities, iron deficiency, vitamin B12 deficiency, and vitamin D deficiency.</p><p>Stool inflammatory markers (fecal calprotectin or lactoferrin) may be elevated due to intestinal inflammation [<a href="#rid15">15</a>]. (See <a class="local">'Stool inflammatory markers'</a> below.)</p><p class="headingAnchor" id="H12689106"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis associated with CD is broad and varies with the site of involvement and the chronicity of the clinical presentation (eg, abdominal pain, diarrhea, weight loss):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infectious colitis</strong> – For patients with diarrhea (especially with acute symptoms), stool studies are performed to evaluate for enteric pathogens (ie, <em>Shigella</em>, <em>Salmonella</em>, <em>Campylobacter</em>, <em>Escherichia coli</em> O157:H7, <em>Yersinia</em>, <em>Clostridioides difficile</em> infection, parasites, and amebiasis. (See  <a class="medical medical_review" href="/z/d/html/2717.html" rel="external">"Approach to the adult with acute diarrhea in resource-abundant settings"</a>.)</p><p></p><p class="bulletIndent1">In immunocompromised patients, cytomegalovirus infection can mimic CD. (See  <a class="medical medical_review" href="/z/d/html/8289.html" rel="external">"Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent adults", section on 'Gastrointestinal manifestations'</a>.)</p><p></p><p class="bulletIndent1">In patients with primarily small bowel involvement, <em>Yersinia</em> can cause an acute ileitis that is difficult to distinguish endoscopically from acute Crohn ileitis. Both tuberculosis and amebiasis can mimic CD of the ileum and cecum. (See  <a class="medical medical_review" href="/z/d/html/5723.html" rel="external">"Giardiasis: Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/2689.html" rel="external">"Causes of acute infectious diarrhea and other foodborne illnesses in resource-abundant settings"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ulcerative colitis</strong> – When CD involves the colon, it must be distinguished from UC because management of these disorders can differ. Clinical features that suggest CD include (see  <a class="medical medical_review" href="/z/d/html/4067.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults", section on 'Differential diagnosis'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Small bowel involvement</p><p class="bulletIndent2"><span class="glyph">•</span>Normal appearing rectal mucosa (ie, rectal sparing) (see <a class="local">'Ileocolonoscopy'</a> below)</p><p class="bulletIndent2"><span class="glyph">•</span>Stools without gross blood</p><p class="bulletIndent2"><span class="glyph">•</span>Perianal disease</p><p class="bulletIndent2"><span class="glyph">•</span>Focal or segmental disease distribution rather than continuous involvement</p><p></p><p class="bulletIndent1">For some patients with IBD, the distinction between CD and UC cannot be made; such patients are referred to as having indeterminate colitis. Some patients may initially be diagnosed with UC or CD but it evolves with time to the other diagnosis. One report suggested that an evolution to a diagnosis of CD was more likely in patients initially diagnosed with UC who presented with non-bloody diarrhea or weight loss [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diverticular colitis </strong>– Diverticular colitis is characterized by inflammation in the interdiverticular mucosa without involvement of the diverticular orifices. In contrast, in patients with IBD and diverticulosis, the inflammation involves the colonic area harboring diverticula, as well as the diverticular orifices [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/z/d/html/2601.html" rel="external">"Segmental colitis associated with diverticulosis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Celiac disease –</strong> Celiac disease is a small bowel disorder characterized by mucosal inflammation and villous atrophy which occur in response to dietary gluten. Patients with celiac disease may present with gastrointestinal symptoms that are similar to CD (eg, diarrhea, weight loss). Serologic evaluation (ie, tissue transglutaminase-IgA antibody) is typically performed to detect celiac disease in adults. The clinical manifestations and diagnosis of celiac disease are presented separately. (See  <a class="medical medical_review" href="/z/d/html/4774.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/4771.html" rel="external">"Diagnosis of celiac disease in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Irritable bowel syndrome – </strong>Gastrointestinal symptoms such as diarrhea and abdominal pain are common to both IBS and IBD. However, patients with IBS do not have abnormal laboratory studies such as fecal calprotectin or C-reactive protein and do not have mucosal inflammation on ileocolonoscopy. (See <a class="local">'Stool inflammatory markers'</a> below and <a class="local">'Laboratory studies'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lactose intolerance – </strong>Intolerance to lactose-containing foods (primarily dairy products) is a common problem and the diagnosis may be initially confused with CD. Clinical symptoms of lactose intolerance include diarrhea, abdominal pain, and flatulence after ingestion of milk or milk-containing products. (See  <a class="medical medical_review" href="/z/d/html/2542.html" rel="external">"Lactose intolerance and malabsorption: Clinical manifestations, diagnosis, and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other disorders –</strong> Because of the segmental nature of CD, patients with a variety of disorders may have similar presenting symptoms and imaging studies. These include appendicitis, diverticulitis, ischemic colitis, and a perforating or obstructing bowel cancer. </p><p></p><p class="bulletIndent1">The clinical presentation of common variable immunodeficiency (CVID) can also resemble CD (eg, diarrhea, weight loss), and the diagnosis of CVID is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3928.html" rel="external">"Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults", section on 'Gastrointestinal disease'</a>.)</p><p></p><p class="headingAnchor" id="H12689148"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H224571352"><span class="h2">Goals</span><span class="headingEndMark"> — </span>Goals of the diagnostic evaluation for a patient with suspected CD are to exclude other causes for symptoms, establish the diagnosis of CD, and determine the severity of disease. (See  <a class="medical medical_review" href="/z/d/html/4069.html" rel="external">"Overview of the medical management of mild (low risk) Crohn disease in adults", section on 'Assessing disease activity, severity, and risk'</a>.)</p><p>The diagnosis of CD may be suspected in patients with compatible clinical features, including symptoms (eg, right lower quadrant abdominal pain, chronic intermittent diarrhea, fatigue, weight loss) and laboratory tests (eg, anemia, vitamin B12 deficiency, vitamin D deficiency).</p><p>The diagnosis of CD is established on the basis of radiologic, endoscopic, and/or histologic findings that demonstrate segmental and transmural inflammation of the luminal gastrointestinal tract in a patient with compatible clinical presentation (eg, abdominal pain, chronic intermittent diarrhea). Laboratory testing is complementary in assessing the severity and complications of CD, but does not establish the diagnosis. </p><p class="headingAnchor" id="H4280811900"><span class="h2">Approach to testing</span><span class="headingEndMark"> — </span>The typical workup for most patients in whom CD is suspected includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory studies including blood tests and, for patients with diarrhea, stool studies. (See <a class="local">'Laboratory studies'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Small bowel imaging (usually magnetic resonance enterography [MRE] where available). (See <a class="local">'Small bowel imaging'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Colonoscopy with intubation of the terminal ileum, including mucosal biopsies. (See <a class="local">'Ileocolonoscopy'</a> below.)</p><p></p><p class="headingAnchor" id="H12689155"><span class="h2">Laboratory studies</span><span class="headingEndMark"> — </span>Laboratory testing is complementary and useful for assessing disease complications, while no single laboratory test can establish the diagnosis of CD [<a href="#rid4">4</a>]. </p><p class="headingAnchor" id="H793481110"><span class="h3">Blood tests</span><span class="headingEndMark"> — </span>Blood tests for patients in whom the diagnosis is suspected include:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Blood chemistry including electrolytes, renal function tests, liver biochemical and function tests, and blood glucose</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum iron, ferritin, vitamin D, and vitamin B12 levels</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>C-reactive protein (CRP)</p><p></p><p>Serum CRP is an acute phase reactant that rises with inflammatory activity and is seen in some patients with IBD [<a href="#rid18">18,19</a>]. Elevated levels of CRP may help differentiate patients with IBD from those with symptoms caused by other disorders (eg, irritable bowel syndrome) [<a href="#rid18">18,20-22</a>]. CRP levels are reported to correlate with CD activity [<a href="#rid23">23,24</a>]. The use of laboratory testing for pretreatment evaluation and for monitoring patients with CD who have achieved clinical remission with medical therapy is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4069.html" rel="external">"Overview of the medical management of mild (low risk) Crohn disease in adults", section on 'Assessing disease activity, severity, and risk'</a> and  <a class="medical medical_review" href="/z/d/html/4069.html" rel="external">"Overview of the medical management of mild (low risk) Crohn disease in adults", section on 'Monitoring during remission'</a>.)</p><p class="headingAnchor" id="H2686625143"><span class="h3">Stool studies</span></p><p class="headingAnchor" id="H1688639344"><span class="h4">Testing for enteric pathogens</span><span class="headingEndMark"> — </span>For patients with diarrhea, a stool specimen is sent for culture, examination for ova and parasites, and for those with risk factors (eg, recent antibiotic use), <em>Clostridioides difficile</em> toxin. The epidemiology, clinical manifestations and diagnosis of <em>Clostridioides difficile</em> infection is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/2696.html" rel="external">"<i>Clostridioides difficile </i>infection in adults: Epidemiology, microbiology, and pathophysiology"</a> and  <a class="medical medical_review" href="/z/d/html/2699.html" rel="external">"<i>Clostridioides difficile </i>infection in adults: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H2342575479"><span class="h4">Stool inflammatory markers</span><span class="headingEndMark"> — </span>Although tests for fecal calprotectin or lactoferrin are not used routinely to diagnose CD, they may help to differentiate patients with intestinal inflammation from patients with functional bowel disease [<a href="#rid4">4,25-27</a>]. While calprotectin is used more commonly by some clinicians, lactoferrin is an acceptable alternative [<a href="#rid27">27,28</a>]. (See  <a class="medical medical_review" href="/z/d/html/2591.html" rel="external">"Approach to the adult with chronic diarrhea in resource-abundant settings", section on 'General laboratory tests'</a>.) </p><p>In selected patients (eg, those in whom it is difficult to distinguish CD from functional bowel disease), we measure fecal calprotectin instead of proceeding directly to ileocolonoscopy. If fecal calprotectin is normal, a diagnosis of IBD is unlikely. If fecal calprotectin level is above the reference range, we proceed with ileocolonoscopy and biopsy to confirm the diagnosis of IBD. </p><p>In a meta-analysis of eight studies including 1062 participants (565 patients with IBD [confirmed by endoscopy], 259 patients with IBS and 238 healthy controls), which evaluated the performance of fecal calprotectin in distinguishing between IBD and IBS, patients with a fecal calprotectin level of &lt;40 microg/g had a 1 percent chance or less of having IBD [<a href="#rid27">27</a>]. In a separate analysis of two studies in the same systematic review (541 participants [275 patients with IBD, 168 patients with IBS and 98 healthy controls]), patients with a fecal lactoferrin level of &lt;10microg/g had a 2 percent chance or less of having IBD. (See  <a class="medical medical_review" href="/z/d/html/2630.html" rel="external">"Clinical manifestations and diagnosis of irritable bowel syndrome in adults", section on 'Laboratory testing'</a>.) </p><p>In an earlier meta-analysis that included six studies with 670 adult patients, the presence of fecal calprotectin was 93 percent sensitive and 96 percent specific for identifying patients with IBD [<a href="#rid15">15</a>], using ileocolonoscopy with histology as the reference standard. </p><p>We also measure fecal calprotectin when evaluating a patient with established CD who had achieved clinical remission but who now presents with symptoms of a disease flare (eg, abdominal pain, diarrhea). In this setting, some clinicians may initiate treatment based on clinical evaluation, but we obtain objective testing (eg, stool markers, laboratory studies) prior to initiating immunosuppressive therapy. </p><p>The use of fecal calprotectin for pretreatment evaluation and for monitoring disease activity in patients with IBD is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4069.html" rel="external">"Overview of the medical management of mild (low risk) Crohn disease in adults"</a> and  <a class="medical medical_review" href="/z/d/html/4084.html" rel="external">"Management of Crohn disease after surgical resection", section on 'Postoperative monitoring'</a>.)</p><p class="headingAnchor" id="H2893457"><span class="h2">Endoscopy</span></p><p class="headingAnchor" id="H12689162"><span class="h3">Ileocolonoscopy</span><span class="headingEndMark"> — </span>Colonoscopy with intubation of the terminal ileum (including mucosal biopsies) is performed for the evaluation of suspected ileocolonic CD. Endoscopic features include focal ulcerations adjacent to areas of normal appearing mucosa along with nodular mucosal changes that result in a cobblestone appearance  (<a class="graphic graphic_picture graphicRef74646" data-inline-graphics="74646" href="/z/d/graphic/74646.html" rel="external">picture 3</a>). (See  <a class="medical medical_review" href="/z/d/html/4072.html" rel="external">"Endoscopic diagnosis of inflammatory bowel disease in adults"</a>.)</p><p>Skip areas of involvement are typical with segments of normal-appearing bowel interrupted by large areas of disease. Pseudopolyps (hypertrophied masses of mucous membrane resembling polyps) may also be present. Normal appearing rectal mucosa (ie, rectal sparing) is common in CD. (See  <a class="medical medical_review" href="/z/d/html/4051.html" rel="external">"Medical management of low-risk adult patients with mild to moderate ulcerative colitis", section on 'Induction of remission'</a>.)</p><p>During colonoscopy, biopsies are obtained from the right colon, left colon, and rectum even if endoscopically normal in appearance to assess for histologic evidence of inflammation. The histologic findings include focal ulcerations and acute and chronic inflammation. These findings are usually confirmatory rather than diagnostic. </p><p>Granulomas may be noted in up to 30 percent of patients with CD and this histologic finding supports but is not required to establish the diagnosis  (<a class="graphic graphic_picture graphicRef81744" href="/z/d/graphic/81744.html" rel="external">picture 4</a>) [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H2582330479"><span class="h3">Other endoscopic examinations</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Upper endoscopy</strong> – Upper endoscopy with biopsies of the stomach and small bowel is performed in patients with suspected CD and upper gastrointestinal symptoms (eg, dyspepsia, early satiety, nausea, emesis). Endoscopic findings consistent with CD include esophageal ulceration, gastric inflammation, and duodenal ulceration and/or inflammation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Video capsule endoscopy</strong> – Video capsule endoscopy (VCE) or wireless video endoscopy, provides an alternative method for visualizing the small bowel mucosa but without radiation exposure. It may detect suggestive lesions (eg, small bowel ulcerations) not visible by other small bowel studies  (<a class="graphic graphic_picture graphicRef76042" href="/z/d/graphic/76042.html" rel="external">picture 5</a>). VCE should not be performed in patients with a suspected intestinal stricture since the capsule may not be able to pass through the stricture, thus requiring surgical or endoscopic removal. (See  <a class="medical medical_review" href="/z/d/html/2652.html" rel="external">"Overview of deep small bowel enteroscopy"</a>.)</p><p></p><p class="bulletIndent1">The use and diagnostic accuracy of VCE are presented separately. (See  <a class="medical medical_review" href="/z/d/html/2662.html" rel="external">"Wireless video capsule endoscopy"</a>.)</p><p></p><p class="headingAnchor" id="H12689169"><span class="h2">Imaging</span></p><p class="headingAnchor" id="H12689183"><span class="h3">Small bowel imaging</span><span class="headingEndMark"> — </span>Small bowel imaging is performed as part of the diagnostic evaluation for patients with suspected CD, because much of the small bowel is not easily accessible by direct endoscopic visualization, and small bowel imaging also demonstrates disease distribution and extent. </p><p>We perform magnetic resonance imaging with small bowel enterography (MRE) for most patients because it avoids radiation and has comparable diagnostic accuracy to computed tomography with small bowel enterography (CTE) [<a href="#rid29">29,30</a>]. Patient evaluation prior to magnetic resonance imaging (MRI) with contrast is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/113082.html" rel="external">"Patient evaluation before gadolinium contrast administration for magnetic resonance imaging"</a> and  <a class="medical medical_review" href="/z/d/html/113084.html" rel="external">"Patient evaluation for metallic or electrical implants, devices, or foreign bodies before magnetic resonance imaging"</a>.)</p><p>MRI with enterography (using a neutral contrast agent to distend the small bowel) demonstrates bowel inflammation, complications (eg, stricturing disease and enteric fistula), and disease distribution and extent [<a href="#rid31">31-33</a>]. MRE features of small bowel inflammation include increased bowel wall enhancement and wall thickness, hyperintensity (possibly reflecting edema), and mucosal lesions (eg, ulcers). </p><p>The sensitivity of MRE with oral and intravenous contrast for detecting inflammation associated with CD is &gt;90 percent [<a href="#rid30">30,34</a>]. In one study, 44 patients with ileal or ileocolonic CD underwent MRE, CTE, and ileocolonoscopy for measurement of disease activity and detection of CD-related complications [<a href="#rid35">35</a>]. Both CTE and MRE demonstrated similar accuracy for disease location, wall thickening and enhancement, enlarged lymph nodes, and involvement of perivisceral fat, but MRE demonstrated higher accuracy in the detection of strictures (0.95 versus 0.91). In per-segment analysis, as compared with CTE, MRE was more accurate in the detection of ileal wall enhancement (0.88 versus 0.81). </p><p>Alternatives to MRE for small bowel imaging include: </p><p class="bulletIndent1"><span class="glyph">●</span>CTE – CTE (with a neutral contrast similar to MRE) is useful for detecting small bowel inflammation and complications (eg, such as intraabdominal abscesses  (<a class="graphic graphic_diagnosticimage graphicRef72882" href="/z/d/graphic/72882.html" rel="external">image 1</a>)), and has a sensitivity of approximately 90 percent [<a href="#rid29">29,36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Upper gastrointestinal series with small bowel follow through – Upper gastrointestinal series with small bowel follow through involves ingestion of a <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">barium</a> solution with subsequent radiologic imaging of the small intestine. Typical features of small bowel CD include narrowing of the lumen with nodularity and ulceration, a "string" sign when luminal narrowing becomes more advanced or with severe spasm, a cobblestone appearance, fistulas and abscess formation, and separation of bowel loops, a manifestation of transmural inflammation with bowel wall thickening  (<a class="graphic graphic_diagnosticimage graphicRef67391 graphicRef80832 graphicRef81129 graphicRef57661 graphicRef53956" href="/z/d/graphic/67391.html" rel="external">image 2A-E</a>). Antral narrowing and segmental stricturing of the duodenum are suggestive of gastroduodenal CD  (<a class="graphic graphic_diagnosticimage graphicRef77013 graphicRef78617" href="/z/d/graphic/77013.html" rel="external">image 3A-B</a>).</p><p></p><p class="bulletIndent1">While <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">barium</a> studies were traditionally part of the evaluation for patients with suspected CD, cross sectional imaging (eg, MRE, CTE) is used more commonly because of greater diagnostic accuracy. In a study of 40 patients with suspected CD, CTE had higher sensitivity compared with small bowel follow through (83 versus 65 percent) [<a href="#rid36">36</a>].</p><p></p><p class="headingAnchor" id="H4240948030"><span class="h3">Other diagnostic imaging</span></p><p class="bulletIndent1"><span class="glyph">●</span>Alternatives to colonoscopy – Colonoscopy is the preferred study for evaluation of the large bowel, while <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">barium</a> enema or computed tomography (CT) colonography are less desirable alternatives because the colon and ileum are not directly visualized and mucosal biopsies cannot be obtained. However, an alternative to optical colonoscopy may be indicated when it cannot be completed for technical reasons (eg, nonobstructing colonic stricture). (See  <a class="medical medical_review" href="/z/d/html/2526.html" rel="external">"Overview of computed tomographic colonography"</a>.)</p><p></p><p class="bulletIndent1">For example, air-contrast <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">barium</a> enema may detect aphthous ulcers and can document the extent of disease and the location and severity of colonic strictures. Sacculations may be seen in patients with chronic involvement  (<a class="graphic graphic_diagnosticimage graphicRef52610 graphicRef75400" href="/z/d/graphic/52610.html" rel="external">image 4A-B</a>). It may also reveal small perforations with fistula tracts.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Perianal and pelvic imaging – MRI of the pelvis is used to detect perianal fistula and define the fistula tract  (<a class="graphic graphic_diagnosticimage graphicRef72435" href="/z/d/graphic/72435.html" rel="external">image 5</a> and <a class="graphic graphic_diagnosticimage graphicRef50476" href="/z/d/graphic/50476.html" rel="external">image 6</a>). The evaluation of a patient with suspected CD and perianal fistula and/or abscess is presented separately. (See  <a class="medical medical_review" href="/z/d/html/4082.html" rel="external">"Perianal Crohn disease"</a> and  <a class="medical medical_review" href="/z/d/html/2580.html" rel="external">"The role of imaging tests in the evaluation of anal abscesses and fistulas"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Investigational methods – Crohn disease activity can be assessed with multispectral optoacoustic tomography (MSOT), a transabdominal imaging technique that detects bowel wall inflammation by quantifying surrogate markers such as hemoglobin-dependent tissue perfusion [<a href="#rid37">37</a>]. MSOT uses the excitation of short-pulsed laser light with near-infrared wavelengths to induce the photoacoustic effect in targeted tissues, which results in sound waves generated by thermoelastic expansion [<a href="#rid38">38</a>]. In a preliminary study using endoscopy as the reference standard in 44 patients with CD, MSOT parameters (ie, total hemoglobin, oxygenated hemoglobin and deoxygenated hemoglobin) successfully distinguished active versus nonactive disease. Results were similar using histology as the reference standard in 42 patients [<a href="#rid37">37</a>]. Although not yet available for use in practice and further validation is needed, this technique holds promise for future clinical application.</p><p></p><p class="headingAnchor" id="H1603148300"><span class="h3">Risks associated with imaging</span><span class="headingEndMark"> — </span>Risks associated with imaging studies include:</p><p class="bulletIndent1"><span class="glyph">●</span>Ionizing radiation – Many examinations (eg, radiographs, CT scans, and fluoroscopic <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">barium</a> studies) expose patients to ionizing radiation, which is associated with an increased risk of malignancy. In one study, the radiation exposure from radiographic studies over a five-year period was assessed in 371 patients with CD [<a href="#rid39">39</a>]. The mean cumulative radiation exposure over five years was 14 milli-Sieverts (mSv), with a range of 0 to 303 mSv. The median cumulative radiation exposure was lower, at 3 mSv. While the majority of patients had a cumulative exposure of less than 50 mSv (a cutoff used by some investigators to identify patients at high risk of complications from radiation exposure), 27 patients (7 percent) had a cumulative exposure of more than 50 mSv. The risks associated with radiation exposure have contributed to increased utilization of alternative imaging techniques that do not require ionizing radiation (eg, MRI), especially in children and young adults [<a href="#rid39">39,40</a>]. (See  <a class="medical medical_review" href="/z/d/html/14613.html" rel="external">"Radiation-related risks of imaging"</a> and  <a class="medical medical_review" href="/z/d/html/5879.html" rel="external">"Clinical presentation and diagnosis of inflammatory bowel disease in children", section on 'Imaging'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gadolinium retention – For patients who have MRI with gadolinium contrast, a small portion of the gadolinium remains in the body for an undetermined duration, and the long-term effects are unknown. Concerns about gadolinium retention are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/113082.html" rel="external">"Patient evaluation before gadolinium contrast administration for magnetic resonance imaging"</a>.)</p><p></p><p class="headingAnchor" id="H12689225"><span class="h1">PROGNOSIS</span></p><p class="headingAnchor" id="H2262182820"><span class="h2">Disease course</span><span class="headingEndMark"> — </span>For many patients with CD, symptoms are chronic and intermittent, but the disease course can vary. Some patients may have a continuous and progressive course of active disease, while approximately 20 percent of patients experience prolonged remission after initial presentation [<a href="#rid41">41,42</a>].</p><p>Chronic bowel inflammation can lead to complications such as strictures, fistula, or abscess. A population-based cohort study showed that the risk of developing intestinal complications among patients with inflammatory CD was 50 percent at 20 years after diagnosis, and ileal involvement was associated with a shorter time interval to onset of complications [<a href="#rid43">43</a>]. </p><p>Risk factors for progressive disease include [<a href="#rid44">44,45</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Age &lt;40 years</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tobacco use</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Perianal or rectal involvement</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Glucocorticoid-requiring disease</p><p></p><p class="headingAnchor" id="H420156171"><span class="h2">Risk of surgery</span><span class="headingEndMark"> — </span>Many patients with CD ultimately require surgical intervention. Although advances in medical therapy have coincided with lower rates of surgical resection in patients with CD, surgery is often required in the setting of bowel obstruction, abscesses, perforation, or refractory disease. The 10-year risk of surgical resection for CD is nearly 50 percent [<a href="#rid46">46</a>]. (See  <a class="medical medical_review" href="/z/d/html/86198.html" rel="external">"Surgical management of Crohn disease"</a>.)</p><p>The management of patients with CD after surgical resection and the risk factors for disease recurrence are presented separately. (See  <a class="medical medical_review" href="/z/d/html/4084.html" rel="external">"Management of Crohn disease after surgical resection"</a>.)</p><p class="headingAnchor" id="H940656260"><span class="h2">Cancer risk</span><span class="headingEndMark"> — </span>The risk of colorectal cancer in longstanding CD involving the colon is probably comparable to UC [<a href="#rid47">47-49</a>]. However, not all studies reached these conclusions and thus the magnitude of risk in patients with CD remains unsettled. These issues, including surveillance for dysplasia, are presented separately. (See  <a class="medical medical_review" href="/z/d/html/4079.html" rel="external">"Surveillance and management of dysplasia in patients with inflammatory bowel disease", section on 'Crohn disease'</a>.)</p><p>Increases in incidence of squamous cell carcinoma of the anus and skin, adenocarcinoma of the small bowel, duodenal neoplasia, testicular cancer, and leukemia have all been reported in CD, although the strength of these associations is unclear [<a href="#rid50">50</a>]. In a retrospective population-based cohort study that included 3348 patients with IBD and no prior cancer history, both the overall cancer risk and the risk of colon cancer was not increased [<a href="#rid51">51</a>]. However, patients with CD had a higher risk of hematologic malignancies (standardized incidence ratios 14, 95% CI 6.7-25.9).</p><p>In addition, patients receiving thiopurine therapy for IBD had an increased risk of developing lymphoproliferative disorders [<a href="#rid52">52,53</a>]. Analyses of lymphoma risk in patients receiving biologic agents directed against tumor necrosis factor-alpha are confounded by concomitant use of immunosuppressive agents in most of these patients. The risk of lymphoma, including hepatosplenic T-cell lymphoma, is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4056.html" rel="external">"Overview of azathioprine and mercaptopurine use in inflammatory bowel disease", section on 'Lymphoma'</a> and  <a class="medical medical_review" href="/z/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults", section on 'Hepatosplenic T-cell lymphoma'</a>.)</p><p class="headingAnchor" id="H720090843"><span class="h2">Mortality</span><span class="headingEndMark"> — </span>Patients with CD may have a slightly higher overall mortality compared with the general population. In a meta-analysis of 35 studies, the standardized mortality ratio (an approximation of the risk of death compared to the general population) was 1.38 (95% CI 1.23-1.55) [<a href="#rid54">54</a>].</p><p class="headingAnchor" id="H2815354626"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109856.html" rel="external">"Society guideline links: Crohn disease in adults"</a>.)</p><p class="headingAnchor" id="H1630024054"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15383.html" rel="external">"Patient education: Crohn disease in adults (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/2004.html" rel="external">"Patient education: Crohn disease (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H12689246"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Background </strong>– Inflammatory bowel disease (IBD) is comprised of two major disorders: ulcerative colitis (UC) and Crohn disease (CD). UC affects the colon and is characterized by inflammation of the mucosal layer. CD is characterized by transmural inflammation and may involve any portion of gastrointestinal tract, from the oral cavity to the perianal area. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features </strong>– The cardinal symptoms of CD include crampy abdominal pain, chronic intermittent diarrhea (with or without gross bleeding), fatigue, and weight loss. The duration of symptoms suggestive of CD is variable. Some patients may present years after the onset of symptoms, while others may present acutely. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1">Transmural bowel inflammation of CD is associated with sinus tracts that may lead to intestinal or perianal fistulas, phlegmon, or abscess. (See <a class="local">'Features of transmural inflammation'</a> above.)</p><p></p><p class="bulletIndent1">Extraintestinal manifestations, such as arthritis or arthropathy, eye and skin disorders, biliary tract involvement, and kidney stones, may occur and are generally related to inflammatory disease activity  (<a class="graphic graphic_table graphicRef81867" href="/z/d/graphic/81867.html" rel="external">table 2</a>). (See <a class="local">'Extraintestinal manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation </strong>– Goals of the diagnostic evaluation of a patient with suspected CD are to exclude other causes for symptoms, establish the diagnosis of CD, and determine the severity of the disease. The diagnosis of CD may be suspected in patients with compatible clinical features including symptoms (eg, right lower quadrant abdominal pain, chronic intermittent diarrhea, fatigue, weight loss) and laboratory tests (eg, anemia, vitamin B12 deficiency, vitamin D deficiency). (See <a class="local">'Goals'</a> above.)</p><p></p><p class="bulletIndent1">The diagnosis of CD is established on the basis of radiologic, endoscopic, and/or histologic findings that demonstrate segmental and transmural inflammation of the luminal gastrointestinal tract in a patient with compatible clinical presentation (eg, abdominal pain, chronic intermittent diarrhea). Laboratory testing is complementary in assessing the severity and complications of CD, but does not establish the diagnosis. </p><p></p><p class="bulletIndent1">The initial workup for patients in whom CD is suspected typically includes (see <a class="local">'Approach to testing'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Laboratory studies including blood tests and, for patients with diarrhea, stool studies (see <a class="local">'Laboratory studies'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Small bowel imaging (usually magnetic resonance enterography where available) (see <a class="local">'Imaging'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Colonoscopy with intubation of the terminal ileum, including mucosal biopsies (see <a class="local">'Ileocolonoscopy'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis </strong>– For many patients with CD, symptoms are chronic and intermittent, but the disease course is variable. Some patients may have a continuous and progressive course of active disease, while approximately 20 percent of patients experience prolonged remission after initial presentation. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1">Many patients with CD ultimately require surgical intervention. Although advances in medical therapy have coincided with lower rates of surgical resection in patients with CD, surgery is often required in the setting of bowel obstruction, abscesses, perforation, or refractory disease. The management of patients with CD after surgical resection and the risk factors for disease recurrence are presented separately. (See  <a class="medical medical_review" href="/z/d/html/4084.html" rel="external">"Management of Crohn disease after surgical resection"</a>.)</p><p></p><p class="headingAnchor" id="H2304566585"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Paul Rutgeerts, MD (deceased), who contributed as a section editor for UpToDate in Gastroenterology.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55:749.</a></li><li><a class="nounderline abstract_t">Pimentel M, Chang M, Chow EJ, et al. Identification of a prodromal period in Crohn's disease but not ulcerative colitis. Am J Gastroenterol 2000; 95:3458.</a></li><li><a class="nounderline abstract_t">Burgmann T, Clara I, Graff L, et al. The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis--how much is irritable bowel syndrome? Clin Gastroenterol Hepatol 2006; 4:614.</a></li><li><a class="nounderline abstract_t">Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol 2018; 113:481.</a></li><li><a class="nounderline abstract_t">Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology 2004; 126:1518.</a></li><li><a class="nounderline abstract_t">Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 2002; 122:875.</a></li><li><a class="nounderline abstract_t">Annunziata ML, Caviglia R, Papparella LG, Cicala M. Upper gastrointestinal involvement of Crohn's disease: a prospective study on the role of upper endoscopy in the diagnostic work-up. Dig Dis Sci 2012; 57:1618.</a></li><li><a class="nounderline abstract_t">Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts. Inflamm Bowel Dis 2011; 17:471.</a></li><li><a class="nounderline abstract_t">Licona Vera E, Betancur Vasquez C, Peinado Acevedo JS, et al. Ocular Manifestations of Inflammatory Bowel Disease. Cureus 2023; 15:e40299.</a></li><li><a class="nounderline abstract_t">Foo WC, Papalas JA, Robboy SJ, Selim MA. Vulvar manifestations of Crohn's disease. Am J Dermatopathol 2011; 33:588.</a></li><li><a class="nounderline abstract_t">Levesque BG, Cipriano LE, Chang SL, et al. Cost effectiveness of alternative imaging strategies for the diagnosis of small-bowel Crohn's disease. Clin Gastroenterol Hepatol 2010; 8:261.</a></li><li><a class="nounderline abstract_t">Obialo CI, Clayman RV, Matts JP, et al. Pathogenesis of nephrolithiasis post-partial ileal bypass surgery: case-control study. The POSCH Group. Kidney Int 1991; 39:1249.</a></li><li><a class="nounderline abstract_t">Silvennoinen JA, Karttunen TJ, Niemelä SE, et al. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995; 37:71.</a></li><li><a class="nounderline abstract_t">Semeao EJ, Stallings VA, Peck SN, Piccoli DA. Vertebral compression fractures in pediatric patients with Crohn's disease. Gastroenterology 1997; 112:1710.</a></li><li><a class="nounderline abstract_t">van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 341:c3369.</a></li><li><a class="nounderline abstract_t">Melmed GY, Elashoff R, Chen GC, et al. Predicting a change in diagnosis from ulcerative colitis to Crohn's disease: a nested, case-control study. Clin Gastroenterol Hepatol 2007; 5:602.</a></li><li><a class="nounderline abstract_t">Tursi A, Elisei W, Giorgetti GM, et al. Inflammatory manifestations at colonoscopy in patients with colonic diverticular disease. Aliment Pharmacol Ther 2011; 33:358.</a></li><li><a class="nounderline abstract_t">Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004; 10:661.</a></li><li><a class="nounderline abstract_t">Magro F, Sousa P, Ministro P. C-reactive protein in Crohn's disease: how informative is it? Expert Rev Gastroenterol Hepatol 2014; 8:393.</a></li><li><a class="nounderline abstract_t">Shine B, Berghouse L, Jones JE, Landon J. C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders. Clin Chim Acta 1985; 148:105.</a></li><li><a class="nounderline abstract_t">Poullis AP, Zar S, Sundaram KK, et al. A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders. Eur J Gastroenterol Hepatol 2002; 14:409.</a></li><li><a class="nounderline abstract_t">Schoepfer AM, Trummler M, Seeholzer P, et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008; 14:32.</a></li><li><a class="nounderline abstract_t">Fagan EA, Dyck RF, Maton PN, et al. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest 1982; 12:351.</a></li><li><a class="nounderline abstract_t">Chamouard P, Richert Z, Meyer N, et al. Diagnostic value of C-reactive protein for predicting activity level of Crohn's disease. Clin Gastroenterol Hepatol 2006; 4:882.</a></li><li><a class="nounderline abstract_t">Sipponen T. Diagnostics and prognostics of inflammatory bowel disease with fecal neutrophil-derived biomarkers calprotectin and lactoferrin. Dig Dis 2013; 31:336.</a></li><li><a class="nounderline abstract_t">Mosli MH, Zou G, Garg SK, et al. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2015; 110:802.</a></li><li><a class="nounderline abstract_t">Menees SB, Powell C, Kurlander J, et al. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol 2015; 110:444.</a></li><li><a class="nounderline abstract_t">Zhou XL, Xu W, Tang XX, et al. Fecal lactoferrin in discriminating inflammatory bowel disease from irritable bowel syndrome: a diagnostic meta-analysis. BMC Gastroenterol 2014; 14:121.</a></li><li><a class="nounderline abstract_t">Siddiki HA, Fidler JL, Fletcher JG, et al. Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn's disease. AJR Am J Roentgenol 2009; 193:113.</a></li><li><a class="nounderline abstract_t">Church PC, Turner D, Feldman BM, et al. Systematic review with meta-analysis: magnetic resonance enterography signs for the detection of inflammation and intestinal damage in Crohn's disease. Aliment Pharmacol Ther 2015; 41:153.</a></li><li><a class="nounderline abstract_t">Masselli G, Casciani E, Polettini E, Gualdi G. Comparison of MR enteroclysis with MR enterography and conventional enteroclysis in patients with Crohn's disease. Eur Radiol 2008; 18:438.</a></li><li><a class="nounderline abstract_t">Lin MF, Narra V. Developing role of magnetic resonance imaging in Crohn's disease. Curr Opin Gastroenterol 2008; 24:135.</a></li><li><a class="nounderline abstract_t">Fidler J. MR imaging of the small bowel. Radiol Clin North Am 2007; 45:317.</a></li><li><a class="nounderline abstract_t">Friedrich C, Fajfar A, Pawlik M, et al. Magnetic resonance enterography with and without biphasic contrast agent enema compared to conventional ileocolonoscopy in patients with Crohn's disease. Inflamm Bowel Dis 2012; 18:1842.</a></li><li><a class="nounderline abstract_t">Fiorino G, Bonifacio C, Peyrin-Biroulet L, et al. Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn's disease. Inflamm Bowel Dis 2011; 17:1073.</a></li><li><a class="nounderline abstract_t">Solem CA, Loftus EV Jr, Fletcher JG, et al. Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc 2008; 68:255.</a></li><li><a class="nounderline abstract_t">Knieling F, Neufert C, Hartmann A, et al. Multispectral Optoacoustic Tomography for Assessment of Crohn's Disease Activity. N Engl J Med 2017; 376:1292.</a></li><li><a class="nounderline abstract_t">Waldner MJ, Knieling F, Egger C, et al. Multispectral Optoacoustic Tomography in Crohn's Disease: Noninvasive Imaging of Disease Activity. Gastroenterology 2016; 151:238.</a></li><li><a class="nounderline abstract_t">Kroeker KI, Lam S, Birchall I, Fedorak RN. Patients with IBD are exposed to high levels of ionizing radiation through CT scan diagnostic imaging: a five-year study. J Clin Gastroenterol 2011; 45:34.</a></li><li><a class="nounderline abstract_t">De Franco A, Di Veronica A, Armuzzi A, et al. Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity. Radiology 2012; 262:680.</a></li><li><a class="nounderline abstract_t">Farmer RG, Whelan G, Fazio VW. Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis. Gastroenterology 1985; 88:1818.</a></li><li><a class="nounderline abstract_t">Solberg IC, Vatn MH, Høie O, et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007; 5:1430.</a></li><li><a class="nounderline abstract_t">Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 2010; 139:1147.</a></li><li><a class="nounderline abstract_t">Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology 2006; 130:650.</a></li><li><a class="nounderline abstract_t">Cosnes J, Bourrier A, Nion-Larmurier I, et al. Factors affecting outcomes in Crohn's disease over 15 years. Gut 2012; 61:1140.</a></li><li><a class="nounderline abstract_t">Frolkis AD, Dykeman J, Negrón ME, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology 2013; 145:996.</a></li><li><a class="nounderline abstract_t">Ekbom A, Helmick C, Zack M, Adami HO. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet 1990; 336:357.</a></li><li><a class="nounderline abstract_t">Friedman S, Rubin PH, Bodian C, et al. Screening and surveillance colonoscopy in chronic Crohn's colitis. Gastroenterology 2001; 120:820.</a></li><li><a class="nounderline abstract_t">Maykel JA, Hagerman G, Mellgren AF, et al. Crohn's colitis: the incidence of dysplasia and adenocarcinoma in surgical patients. Dis Colon Rectum 2006; 49:950.</a></li><li><a class="nounderline abstract_t">Hemminki K, Li X, Sundquist J, Sundquist K. Cancer risks in Crohn disease patients. Ann Oncol 2009; 20:574.</a></li><li><a class="nounderline abstract_t">Wang LH, Yang YJ, Cheng WC, et al. Higher Risk for Hematological Malignancies in Inflammatory Bowel Disease: A Nationwide Population-based Study in Taiwan. Am J Gastroenterol 2016; 111:1313.</a></li><li><a class="nounderline abstract_t">Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374:1617.</a></li><li><a class="nounderline abstract_t">Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011; 9:36.</a></li><li><a class="nounderline abstract_t">Bewtra M, Kaiser LM, TenHave T, Lewis JD. Crohn's disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis. Inflamm Bowel Dis 2013; 19:599.</a></li></ol></div><div id="topicVersionRevision">Topic 4070 Version 53.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16698746" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11151877" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Identification of a prodromal period in Crohn's disease but not ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16630762" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis--how much is irritable bowel syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29610508" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : ACG Clinical Guideline: Management of Crohn's Disease in Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15168364" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11910338" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22350786" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Upper gastrointestinal involvement of Crohn's disease: a prospective study on the role of upper endoscopy in the diagnostic work-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20725943" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37448411" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Ocular Manifestations of Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21697699" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Vulvar manifestations of Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19896559" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cost effectiveness of alternative imaging strategies for the diagnosis of small-bowel Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1895677" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pathogenesis of nephrolithiasis post-partial ileal bypass surgery: case-control study. The POSCH Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7672685" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A controlled study of bone mineral density in patients with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9136852" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Vertebral compression fractures in pediatric patients with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20634346" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17478347" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Predicting a change in diagnosis from ulcerative colitis to Crohn's disease: a nested, case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21133960" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Inflammatory manifestations at colonoscopy in patients with colonic diverticular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15472532" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : C-reactive protein as a marker for inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24635486" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : C-reactive protein in Crohn's disease: how informative is it?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3995779" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11943955" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17924558" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6814926" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16630759" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Diagnostic value of C-reactive protein for predicting activity level of Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24246984" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Diagnostics and prognostics of inflammatory bowel disease with fecal neutrophil-derived biomarkers calprotectin and lactoferrin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25964225" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25732419" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25002150" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Fecal lactoferrin in discriminating inflammatory bowel disease from irritable bowel syndrome: a diagnostic meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19542402" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25403954" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Systematic review with meta-analysis: magnetic resonance enterography signs for the detection of inflammation and intestinal damage in Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17899102" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Comparison of MR enteroclysis with MR enterography and conventional enteroclysis in patients with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18301262" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Developing role of magnetic resonance imaging in Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17502220" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : MR imaging of the small bowel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22231897" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Magnetic resonance enterography with and without biphasic contrast agent enema compared to conventional ileocolonoscopy in patients with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21484958" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18513722" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28355498" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Multispectral Optoacoustic Tomography for Assessment of Crohn's Disease Activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27269244" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Multispectral Optoacoustic Tomography in Crohn's Disease: Noninvasive Imaging of Disease Activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20679907" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Patients with IBD are exposed to high levels of ionizing radiation through CT scan diagnostic imaging: a five-year study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22157203" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3922845" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18054751" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20637205" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16530505" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Predictors of Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22387526" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Factors affecting outcomes in Crohn's disease over 15 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23896172" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1975343" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Increased risk of large-bowel cancer in Crohn's disease with colonic involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11231935" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Screening and surveillance colonoscopy in chronic Crohn's colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16729218" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Crohn's colitis: the incidence of dysplasia and adenocarcinoma in surgical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18765463" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Cancer risks in Crohn disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27296944" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Higher Risk for Hematological Malignancies in Inflammatory Bowel Disease: A Nationwide Population-based Study in Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19837455" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20888436" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23388544" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Crohn's disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
